Hyun-Gyu Lee
Net worth: 4 M $ as of 30/04/2024
Profile
Hyun-Gyu Lee worked as a Director at Enlivex Therapeutics Ltd.
before obtaining a doctorate degree from Seoul National University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 13/09/2023 | 36,000 ( 0.55% ) | 4 M $ | 30/04/2024 |
Former positions of Hyun-Gyu Lee
| Companies | Position | End |
|---|---|---|
Enlivex Therapeutics Ltd. /Old/
 Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Director/Board Member | - |
Training of Hyun-Gyu Lee
| Seoul National University | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
- Stock Market
- Insiders
- Hyun-Gyu Lee
